Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2a, Multi-center, Open-Label, Dose-escalating Study to Assess Safety, Tolerability, and Pharmacokinetics of Intravenously Administered IPL344 for The Treatment of Amyotrophic Lateral Sclerosis (ALS)

Trial Profile

Phase 1/2a, Multi-center, Open-Label, Dose-escalating Study to Assess Safety, Tolerability, and Pharmacokinetics of Intravenously Administered IPL344 for The Treatment of Amyotrophic Lateral Sclerosis (ALS)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Feb 2019

At a glance

  • Drugs IPL-344 (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions
  • Sponsors Immunity Pharma
  • Most Recent Events

    • 05 Sep 2018 New trial record
    • 14 Aug 2018 According to an Immunity Pharma media release, phase 2b portion could be the basis for a conditional regulatory approval of the drug for the benefit of ALS patients.
    • 14 Aug 2018 According to an Immunity Pharma media release, the first report of the trial outcomes is expected in mid-2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top